Large-scale testing (Phase 3)Study completedNCT02766335
What this trial is testing
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Who this might be right for
Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7
SWOG Cancer Research Network 116